Visus Therapeutics raises $36M from J&J’s VC arm, others to develop eye drop that treats presbyopia
March 10, 2021 at 8:22 am News Brief
Visus Therapeutics, a Seattle-based startup developing a presbyopia-correcting eye drop, raised $36 million. Johnson & Johnson Innovation, the venture capital arm of J&J, invested in the Series A round, in addition to RTW Investments, LP, Wille AG, and existing backers.
The company’s lead asset, BRIMOCHOL, is a once-daily eye drop that aims to treat presbyopia, a vision condition caused by aging that can make tasks such as reading difficult. It affects about 123 million adults in the U.S., according to the company. Existing treatments include glasses, contact lenses, or surgery.